BioMarin Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $50 million of 1.25% Senior Subordinated Convertible Notes due 2027PRNewsWire • 05/19/20
BioMarin Blows Past Q1 Estimates, Projects 1st Year of Profitability in 2020The Motley Fool • 04/30/20
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/30/20
Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy TreatmentSeeking Alpha • 04/15/20
Vertex Pharmaceuticals And BioMarin Pharmaceutical: 2 Safe Biotech Picks To Buy During This Bear MarketSeeking Alpha • 04/07/20
BioMarin (BMRN) Down 8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/27/20
Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered MondayThe Motley Fool • 03/16/20
Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20